Penny Biotech Growing Stock Alert: EyePoint Pharmaceuticals

Not all healthcare stocks have a gaining movement now when COVID-19 seems to be wiped out soon. On over 3 million shares EyePoint (NASDAQ: EYPT) surges more than 15%. Since January EYPT has been losing points seriously due to poor investor relations approach in lifting the price of shares.

However, the EPS is very close to zero meaning that earnings are still seen on financial reports due to sufficient revenue. Smart traders would buy several lots of shares to back possible losses in the investment portfolio.

Less than $1 EYPT could surge further as IR improves with a smart way from the top management which try to increase market capitalization.

Jack Dawkins

Finance and Tech Contributor

Jack Dawkins has 1680 posts and counting. See all posts by Jack Dawkins